AstraZeneca's Seroquel XR receives complete response letter for GAD
This article was originally published in Scrip
Executive Summary
The US FDA has issued AstraZeneca with a complete response letter for its antipsychotic Seroquel XR (quetiapine fumarate) extended-release tablets for the treatment of generalised anxiety disorder (GAD) in adults.